Loading
A phase 1 trial of CFI-402257 run by University Health Network, Toronto, completed.
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT02792465 by University Health Network, Toronto, with 52 participants enrolled, started 2016-11-11. Conditions recorded: Advanced Solid Cancers and Breast Cancer. Interventions recorded: CFI-402257 and Fulvestrant.
Shares CFI-402257, Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares CFI-402257, Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Treadwell Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CFI-402257, Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/